Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

Murky documentation of meetings between Biogen and the FDA, plus an “unjustifiably high price” for a drug that lacked clinical data, are at fault for the Adulelm controversy, two House committees said ...

Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. The drugmaker said Monday that ...

The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, ...

Dementia expert Dr. Jason Karlawish told CNBC he's skeptical of the Food and Drug Administration's approval of Biogen's Alzheimer's disease drug, Aduhelm, saying "the evidence to approve the drug wasn ...

CMS intends for Medicare to cover Aduhelm, Biogen’s Alzheimer’s disease treatment, for patients taking part in clinical trials, the agency announced Jan. 11. The national coverage determination ...

Department of Health and Human Services Secretary Xavier Becerra announced Monday that he has ordered Medicare to "reassess" the agency's 2022 premium rate hike for Medicare Part B, citing Biogen's ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...